RETRACTED ARTICLE: Therapeutic stimulation of
            GLP-1 and GIP protein with DPP-4 inhibitors for type-2 diabetes treatment

Sharma, Ajay; Paliwal, Geetanjali; Upadhyay, Nisha; Tiwari, Archana

doi:10.1186/s40200-015-0143-4

Cited by 16 publications

(12 citation statements)

References 99 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…When endogenous glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) levels are increased, DPP-4 inhibitors promote insulin release from islet β cells and inhibit glucagon secretion from islet α cells to decrease the blood glucose level [ 35 ]. It has been reported that DPP-4Is might exert some of their effects on insulin secretion by preserving intact GLP-1 and GIP secreted from alpha cells, although the insulinotropic effect of GIP has been shown to be reduced in patients with type 2 diabetes [ 36 – 38 ]. Several studies have found no definitive evidence supporting the cardiovascular benefits of DPP-4 inhibitors or TZDs [ 39 – 43 ].…”

Section: Discussionmentioning

confidence: 99%

Comparison of Oral Antidiabetic Drugs as Add-On Treatments in Patients with Type 2 Diabetes Uncontrolled on Metformin: A Network Meta-Analysis

et al. 2018

View full text Add to dashboard Cite

We assessed the efficacy and safety of oral antidiabetic drugs (OADs) as an add-on treatment in patients with type 2 diabetes uncontrolled on metformin. PubMed, the Cochrane Library, and Embase were searched from inception to October 20, 2017. Pairwise and network meta-analyses were conducted using Stata 14.1 software. Odds ratios (ORs) and weighted mean differences (WMDs) were used to evaluate outcomes. Sixty-eight trials including 36,746 patients were analyzed. No significant differences in the risk of major adverse cardiovascular events (MACEs) and all-cause mortality were observed among any class of OADs when combined with metformin. All classes of OADs as add-ons to metformin improved glucose control, while sodium-glucose co-transporter-2 (SGLT-2) inhibitors showed greater fasting plasma glucose (FPG) reductions {WMD, − 1.49 [95% confidence interval (CI) − 1.69 to − 1.28] mmol/l} and 2 h postprandial glucose (2 h PPG) reductions [WMD, − 3.07 (95% CI − 4.12 to − 2.03) mmol/l]. Thiazolidinediones and sulfonylureas were associated with weight gain [WMD, 2.53 (95% CI 1.95–3.10) kg and 2.00 (95% CI 1.63–2.36) kg, respectively] when added to metformin. Sulfonylureas [WMD, 6.52 (95% CI 4.07–10.45)] were associated with the highest ORs of hypoglycemia. Our results suggest that the seven classes of OADs were not associated with any increased risk of MACEs or all-cause mortality when combined with metformin. Most OADs were associated with similarly large reductions in HbA1c levels when added to metformin, while SGLT-2 inhibitors might be the best option for reducing body weight, FPG, and 2-h PPG.Electronic supplementary materialThe online version of this article (10.1007/s13300-018-0482-5) contains supplementary material, which is available to authorized users.

show abstract

Section: Discussionmentioning

confidence: 99%

Comparison of Oral Antidiabetic Drugs as Add-On Treatments in Patients with Type 2 Diabetes Uncontrolled on Metformin: A Network Meta-Analysis

et al. 2018

View full text Add to dashboard Cite

show abstract

“…The studies of oral glucose tolerance test on animals showed that genetic deletion of DPP-IV have improved glucose tolerance and increased the insulin secretion [5] . In the other hand, the complete data of long term use of synthetic drugs of DPP-IV inhibitor have not been obtained yet, especially on its safety [6] . It induces the research of DPP-IV inhibitor compounds from herbs that are of less side effects, cheaper and easier to get.…”

Section: Introductionmentioning

confidence: 95%

Anti-diabetic potential of Urena lobata leaf extract through inhibition of dipeptidyl peptidase IV activity

Purnomo

Soeatmadji

Sumitro

et al. 2015

Asian Pacific Journal of Tropical Biomedicine

View full text Add to dashboard Cite

Objective: To evaluate the anti-diabetic potential of leaf extract from Urena lobata (U. lobata) through dipeptidyl peptidase IV (DPP-IV) inhibitory activity. Methods: U. lobata leaf was extracted in hot water and ethanol. The activity of DPP-IV inhibitor was tested by in vitro study using gly-pro-p-nitroanilide as substrat of DPP-IV and vildagliptin, as standard reference. A product of the reactions between gly-pro-pnitroanilide and DPP-IV, was observed by microplate readers with l = 405 nm. All data were expressed as mean ± SD and the IC 50 value was determined by non linear regression curve fit. Active substances in leaf extract of U. lobata was analyzed by liquid chromatography-mass spectrometry. DPP-IV inhibitory activity of active compounds was evaluated in silico using docking server. Results: The ethanolic extract of U. lobata showed stronger DPP-IV inhibitor activity than water extract with the IC 50 values of 1 654.64 and 6 489.88 mg/mL, respectively.Vildagliptin, based on standard reference for DPP-IV inhibitor activity, has IC 50 value of 57.44 mg/mL. Based on in silico analysis, mangiferin, stigmasterol and b-sitosterol in U. lobata extract have a strong inhibitory activity on DPP-IV. Conclusions: The results showed that DPP-IV inhibitory activity of U. lobata is related to its active compounds such as mangiferin, stigmasterol and b-sitosterol.

show abstract

“…It stimulates pancreas to release insulin and maintain glucose hemostatic level without any hyperglycemia. In addition, GLP-1 is rapidly degraded by the enzyme DPP-4 and it is no longer available in active form (17). In DM patients, the GLP1 level is reduced and the DPP4 level is increased and this in turn will cause the glucose hemostatic imbalance.…”

Section: Introductionmentioning

confidence: 99%

Impact of exercise training on dipeptidyl peptidase 4 and insulin-like growth factor binding protein 1 in patients with coronary artery disease: Relationship to nitric oxide response

Simonovic¹,

Deljanin-Ilić²,

Kocić³

et al. 2019

Acta fac medic Naissensis

View full text Add to dashboard Cite

Dipeptidyl peptidase 4 (DPP4) is a proteolytic enzyme, involved in a wide range of different cellular functions and expressed on the surface of most cell types, including the endothelium. The circulating level of insulin-like growth factor (IGF) binding protein 1(BP1) is associated with insulin resistance and diabetes, but it also affects the prognosis and mortality of CV diseases. The aim of the study was to evaluate the effects of exercise training on DPP4 and circulating IGF BP1, and to assess their relationship to nitric oxide (NOx), a circulating marker of endothelial function, in patients with stable coronary artery disease (CAD). An overall of 48 subjects was involved in the study, including 28 patients with stable CAD (CAD group, 59.2 ± 8.2 years) and 20 healthy controls (C group, 57.1 ± 8.2 years). At baseline, DPP4, IGF BP1 and NOx, as well as an exercise test, were performed in both groups. After the initial study, CAD group underwent a supervised three-week exercise training at a residential center, and after that period DPP4, IGF BP1, NOx and exercise tolerance were determined again. At baseline, both DPP4 and IGF BP1 were significantly (p = 0.023 and p = 0.021) higher in CAD group, compared to the C group. Since both DPP4 and IGF BP1 significantly decreased in CAD group (p = 0.002 and p = 0.026, respectively) after three weeks of exercise, there were no significant differences between CAD and C groups in DPP4 and IGF BP1 at the end of the study. NOx was significantly lower in CAD group at baseline compared to the C group (p = 0.032). Since it significantly increased in CAD group (p = 0.028), there were no significant differences between groups after three weeks of exercise. Exercise capacity was significantly lower

show abstract

RETRACTED ARTICLE: Therapeutic stimulation of GLP-1 and GIP protein with DPP-4 inhibitors for type-2 diabetes treatment

Cited by 16 publications

References 99 publications

Comparison of Oral Antidiabetic Drugs as Add-On Treatments in Patients with Type 2 Diabetes Uncontrolled on Metformin: A Network Meta-Analysis

Comparison of Oral Antidiabetic Drugs as Add-On Treatments in Patients with Type 2 Diabetes Uncontrolled on Metformin: A Network Meta-Analysis

Anti-diabetic potential of Urena lobata leaf extract through inhibition of dipeptidyl peptidase IV activity

Impact of exercise training on dipeptidyl peptidase 4 and insulin-like growth factor binding protein 1 in patients with coronary artery disease: Relationship to nitric oxide response

Contact Info

Product

Resources

About